| Literature DB >> 32089650 |
Weijian Zhang1,2, Zhigang Huang1, Mingyuan Huang1,2, Jincheng Zeng2.
Abstract
Enterovirus 71 (EV71) is one of the most common intestinal virus that causes hand, foot, and mouth disease (HFMD) in infants and young children (mostly ≤5 years of age). Generally, children with EV71-infected HFMD have mild symptoms that resolve spontaneously within 7-14 days without complications. However, some EV71-infected HFMD cases lead to severe complications such as aseptic meningitis, encephalitis, acute flaccid paralysis, pulmonary edema, cardiorespiratory complication, circulatory disorders, poliomyelitis-like paralysis, myocarditis, meningoencephalitis, neonatal sepsis, and even death. The mechanism of EV71 pathogenesis has been studied extensively, and the regulation of host immune responses is suspected to aggravate EV71-induced severe complications. Recently, several cytokines or chemokines such as TNF-α, IFN-γ, IL-1β, IL-18, IL-33, IL-37, IL-4, IL-13, IL-6, IL-12, IL-23, IL-27, IL-35, IL-10, IL-22, IL-17F, IL-8, IP-10, MCP-1, G-CSF, and HMGB1 have been reported to be associated with severe EV71 infection by numerous research teams, including our own. This review is aimed at summarizing the pathophysiology of the cytokines and chemokines with severe EV71 infection.Entities:
Year: 2020 PMID: 32089650 PMCID: PMC7013319 DOI: 10.1155/2020/9273241
Source DB: PubMed Journal: Mediators Inflamm ISSN: 0962-9351 Impact factor: 4.711
Figure 1Study design and retrieval strategy.
The association between cytokines, chemokines, and EV71-infected HFMD.
| Cytokines/chemokines (sources) | Countries/regions | Study type | Sample type | Complications/severe cases | OR/ROC | Level/value | Progression |
| Study (year) |
|---|---|---|---|---|---|---|---|---|---|
| TNF- | China-Zhengzhou | Case-control | Serum | Fatal cases ( | 4.325 | Peak value | The 2nd day | 0.003 < 0.001 | Duan et al. (2014) [ |
| China-Shandong | Case-control | Serum | NPE ( | 4.593 | Elevated | The 3rd day | 0.001 | Sun et al. (2018) [ | |
| China-Zhejiang | Case-control | Serum | Severe ( | — | Elevated | Hospitalized | <0.01 | Zheng et al. (2017) [ | |
|
| |||||||||
| IFN- | China-Zhengzhou | Case-control | Serum | Fatal cases ( | 4.325 | Low | The 2nd day | 0.017 | Duan et al. (2014) [ |
| China-Shandong | Case-control | Serum | NPE ( | 4.593 | Elevated | The 1st day | <0.01 | Sun et al. (2018) [ | |
| China-Qingdao | Case-control | Blood | Encephalitis ( | 2.04 | (A allele) | — | <0.01 | Yang et al. (2012) [ | |
| Taiwan | Case-control | Plasma | ANSD ( | — | Elevated | — | 0.048 | Wang et al. (2003) [ | |
|
| |||||||||
| IL-1 | Malaysian | Case-control | Serum, CSF | AM ( | — | Elevated | Hospitalized | 0.013 | Griffiths et al. (2012) [ |
| China-Nanjing | Case-control | Plasma, CSF | Severe ( | 2.168 | Elevated | Acute stage | <0.05 | Ye et al. (2015) [ | |
|
| |||||||||
| IL-6 (Th2, M | Taiwan | Case-control | CSF, serum | E (12), PLS (3), AM (7), PE (8) | — | Elevated | The 2nd day | <0.001 | Lin et al. (2003) [ |
| China-Zhengzhou | Case-control | Serum | Fatal cases ( | 4.325 | Elevated | 2-3 days | 0.003 | Duan et al. (2014) [ | |
| China-Zhejiang | Case-control | Serum | Severe ( | — | Elevated | Hospitalized convalescence | <0.01 | Zheng et al. (2017) [ | |
| China-Guangdong | Case-control | Serum | Stages II ( | — | Elevated | TP0 | <0.01 | Chen et al. (2014) [ | |
| China-Qingdao | Case-control | CSF, serum | Encephalitis ( | 3.31 | (G allele) | — | <0.001 | Yuan et al. (2015) [ | |
| Korea, Seoul | Case-control | Serum | Aseptic meningitis ( | 7.44/AUC = 0.95 | Elevated | — | <0.001 | Lee et al. (2018) [ | |
|
| |||||||||
| IL-8 (M | China-Shandong | Case-control | Plasma | Severe ( | 1.8 | (T allele) | — | 0.012 | Xu et al. (2016) [ |
| China-Nanjing | Case-control | Plasma | Severe ( | 2.168 | Elevated | Acute stage | <0.05 | Ye et al. (2015) [ | |
| China-Shenzhen | Case-control | Serum | Severe ( | AUC = 0.46 | Elevated | — | <0.001 | He et al. (2019) [ | |
| Beijing | Case-control | Serum | Mild ( | — | Peak value | The 6th day | <0.001 | Han et al. (2014) [ | |
| Beijing | Case-control | Serum | BE ( | 5.833 | Peak value | The 1st day | NS | Wang et al. (2014) [ | |
|
| |||||||||
| IL-4 (Th2) | China-Zhengzhou | Case-control | Serum | Fatal cases ( | 4.325 | Elevated | 2-4 days | 0.001 | Duan et al. (2014) [ |
| China | Case-control | Serum | Viral encephalitis ( | 15.721 | Elevated | — | <0.001 | Zhang et al. (2015) [ | |
| Beijing | Case-control | Serum | Mild ( | — | Higher | 2-6 days | <0.001 | Han et al. (2014) [ | |
|
| |||||||||
| IL-10 (Th2, M | Taiwan | Case-control | Plasma | ANSD ( | — | Elevated | — | <0.001 | Wang et al. (2003) [ |
| China-Shandong | Case-control | Serum | NPE ( | 4.593 | Elevated | The 3rd day | 0.001 | Sun et al. (2018) [ | |
| China-Qingdao | Case-control | Plasma | Severe ( | 2.998 | (C allele) | — | <0.01 | Zhao et al. (2017) [ | |
| China-Guangdong | Case-control | Serum | Stages II ( | — | Elevated | TP0 | <0.01 | Chen et al. (2014) [ | |
| China-Qingdao | Case-control | Blood | Encephalitis ( | 1.86 | (A allele) | — | <0.05 | Yang et al. (2012) [ | |
|
| |||||||||
| IL-12 (Th1) | China-Hangzhou | Case-control | Plasma | Mild ( | — | Elevated | Within 24 h | <0.01 | Shang et al. (2017) [ |
|
| |||||||||
| IL-13 (Th2) | Taiwan | Case-control | Plasma | ANSD ( | — | Elevated | — | 0.048 | Wang et al. (2003) [ |
| China-Guangdong | Case-control | Serum | Stages II ( | — | Elevated | TP0 | <0.01 | Chen et al. (2014) [ | |
| China-Dongying | Case-control | Serum | Severe ( | 0.969 | (G allele) | — | >0.05 | Zhang et al. (2019) [ | |
|
| |||||||||
| IL-17F (Th17) | China-Qingdao | Case-control | Blood | Encephalitis ( | 0.31 | (C allele) | — | 0.006 | Lv et al. (2013) [ |
| China-Qingdao | Case-control | Blood | Severe ( | 1.916 | (T allele) | — | 0.001 | Li et al. (2018) [ | |
|
| |||||||||
| IL-18 (Th1) | Beijing | Case-control | Serum | Mild ( | — | Peak value | The 3th day | <0.001 | Han et al. (2014) [ |
|
| |||||||||
| IL-22 (Th17, Th22) | China | Case-control | Serum | Viral encephalitis ( | 8.28 | Elevated | — | 0.026 | Zhang et al. (2015) [ |
| China-Zhejiang | Case-control | Plasma | Mild ( | — | Elevated | — | <0.01 | Cui et al. (2017) [ | |
|
| |||||||||
| IL-23 (DC, M | China | Case-control | Serum | Viral encephalitis ( | 4.564 | Elevated | — | 0.002 | Zhang et al. (2015) [ |
|
| |||||||||
| IL-33 (DC, M | Shenzhen | Case-control | Plasma | Severe ( | 2.348 | Elevated | Hospitalized | <0.01 | Zhang et al. (2013) [ |
|
| |||||||||
| IL-27 (APC) | China-Guangzhou | Case-control | Serum | Stages II ( | — | — | TP0 | — | Huang et al. (2016) [ |
|
| |||||||||
| IL-35 (Treg) | China-Henan | Case-control | Serum | Mild ( | — | Declined | — | <0.0001 | Huang et al. (2017) [ |
|
| |||||||||
| IL-37 (APC) | China-Hefei | Case-control | Blood | Patients ( | — | Elevated | — | <0.05 | Lv et al. (2019) [ |
|
| |||||||||
| IP-10 (M | Shenzhen | Case-control | Plasma | Severe ( | 2.348 | Elevated | Hospitalized | <0.01 | Zhang et al. (2013) [ |
| China-Qingdao | Case-control | Blood | Patients ( | 0.35 | (T allele) | — | <0.05 | Yang et al. (2013) [ | |
|
| |||||||||
| MCP-1 (M | China-Hangzhou | Case-control | Plasma | Mild ( | — | Elevated | Within 24 h | <0.01 | Shang et al. (2017) [ |
| Shenzhen | Case-control | Plasma | Acute RF ( | 2.348 | Elevated | Hospitalized | <0.01 | Zhang et al. (2013) [ | |
|
| |||||||||
| RANTES (NK, CD8+) | China-Hangzhou | Case-control | Plasma | Mild ( | — | Elevated | Within 24 h | <0.01 | Shang et al. (2017) [ |
|
| |||||||||
| HMGB1 (M | China-Zhejiang | Case-control | Serum | Severe ( | — | Elevated | Hospitalized recovered | <0.01 | Zheng et al. (2017) [ |
|
| |||||||||
| G-CSF (EC, FB) | Malaysian | Case-control | CSF | AM ( | — | Elevated | Hospitalized | <0.01 | Griffiths et al. (2012) [ |
Mφ: monocytes/macrophages; Th: helper T lymphocytes; DC: dendritic cells; APC: antigen-presenting cells; Treg cells: regulatory T cells; NK: natural killer cell; EC: endothelial cells; FB: fibroblasts; E: encephalitis; AM: aseptic meningitis; AFP: acute flaccid paralysis; NPE: neurogenic pulmonary edema; CNSF: central nervous system failure; CSF: cerebrospinal fluid; PLS: poliomyelitis-like syndrome; BE: brainstem encephalitis; PE: pulmonary edema; CRC: cardiorespiratory complication; RF: respiratory failure; CC: circulatory collapse; BH: brain hernia; GT: gastrointestinal symptoms; MI: myocardial injury; ANSD: autonomic nervous system dysregulation; AUC: area under the curve; IP-10: interferon-induced protein 10; MCP-1: monocyte chemoattractant protein-1; HMGB1: high mobility group protein 1; G-CSF: granulocyte colony-stimulating factor. Stage II means involvement of the nervous system; stage III means early cardiopulmonary failure; and stage IV means cardiopulmonary failure. TP0 means the day of admission; TP1 means the day the disease improved; and TP3 means the day the disease recovered.